2024年10月，蘇州晶云藥物科技股份有限公司（以下簡稱“晶云藥物”）即將參與一系列重要的線下行業(yè)活動，我們誠摯地邀請您與我們一同相聚蘇州、San Francisco、San Diego以及Salt Lake City，共同探討行業(yè)前沿，分享創(chuàng)新技術(shù)。
行業(yè)會議
01
SAPA-China 2024
醫(yī)藥產(chǎn)業(yè)大會
10/18-19 | 蘇州
“SAPA-China 2024醫(yī)藥產(chǎn)業(yè)大會-弘揚創(chuàng)新合作，加快產(chǎn)業(yè)融合”將于2024年10月18-19日在蘇州·獅山國際會議中心舉辦。屆時將有7000余位來自全球頂尖科研機構(gòu)的學(xué)者以及大型跨國制藥及生物技術(shù)創(chuàng)新企業(yè)領(lǐng)軍人物等參會,大會圍繞大/小分子、細(xì)胞基因治療、AI制藥、核酸GLP-1與代謝、臨床、核素偶聯(lián)藥物、出海合作、投融資等熱點領(lǐng)域主題,舉辦高層論壇專題論壇、項目對接、融資推介、企業(yè)展示等系列活動。
時間：2024年10月18-19日
地點：蘇州獅山國際會議中心
展位：A23
海外活動
02
The 16th Drug Discovery Strategic Summit (DDSS) - San Francisco
10/9-10 PDT | San Francisco, CA
Date: October 9-10, 2024
Location: San Francisco Airport Marriott Waterfront
Booth: 3
Attendee: Robert Wenslow, Ph.D. (Speaker) & Ridwan Islam, Ph.D.
Presentation title:
“The Best Use of 10 mg” - Achieve CMC Success through a Unique Optimization of Compound Benchwork and Computational Analysis
Abstract: Small Molecule drug discovery scientists have been trained to believe that they need gram scale quantities of API to determine CMC properties such as solubility, oral absorption, and salt selection to understand the formulation strategy. Crystal Pharmatech will unveil its proven approach to understanding the developmental risks through focused laboratory work and the most advanced computational approaches. You will understand how, with only 10 mg of material, you can move from late lead-op to FIH with a line-of-sight of your compound’s development path and significantly enhance your probability of success in the clinic.
Link: https://ddsswc.agilefalconsg.com/event-guide/
03
Formulation & Delivery US 2024
10/16-17 PDT | San Diego, CA
Date: October 16-17, 2024
Location: DoubleTree by Hilton Hotel San Diego - Mission Valley
Booth: 12
Attendee: Jessica (Xiaoxia) Chen, Ph.D. (Speaker) & Decheng Ma, Ph.D.
Presentation title:
First in Human (FIH) Tablet Development for an Amorphous Unstable Prodrug with Enteric Coating Using an API Sparing Approach
Abstract: This presentation will explore the formulation and development process of First-In-Human (FIH) enteric-coated tablets at three dose strengths for an amorphous prodrug highly susceptible to hydrolysis under both acidic and basic conditions. We will delve into the scientific approaches employed to mitigate degradation pathways, ensure product stability through carefully selected excipients and optimized manufacturing techniques, and how material science-based approaches can lead to successful FIH product development within tight timelines.
Link: https://oxfordglobal.com/discovery-development/events/formulation-delivery-us-2024
04
AAPS 2024 PHarmSCi 360
10/20-23 MDT | Salt Lake City, UT
Meet with industry leadership to discuss:
Developability Assessment
API Form and Solid-State Research
Formulation Development
Clinical and Commercial Manufacturing
Biologics Analytical Services
Date: October 20-23, 2024
Location: Salt Palace Convention Center, Salt Lake City, UT
Attendee: Alex Chen, Ph.D. & Robert Wenslow, Ph.D. & Decheng Ma, Ph.D. & Ridwan Islam, Ph.D.
Booth: 3139
Link: https://www.aaps.org/pharmsci/annual-meeting
